John E. Dillberger, DVM, Ph.D., DACVP, DABT, FIATP, is a Strategic Consultant with EBG Advisors, Inc.  Dr. Dillberger is president of a nonclinical development consulting company specializing in the application of toxicology, pathology, and pharmacology expertise to the safety evaluation of drugs, biologics, medical devices, imaging agents, diagnostic agents, and combination products. His clients include biopharmaceutical companies in North America, Europe, the Middle East, Asia, Australia, and New Zealand; nonprofit foundations; investment firms with pharmaceutical company portfolios; and law firms needing an expert witness in toxicology.

He is the author of numerous scientific papers and a book chapter entitled “Nonclinical Development of Drugs and Biologics: Pharmacology and Toxicology,” serves as reviewer for Antimicrobial Agents and Chemotherapy, and has served two terms on the editorial board of Veterinary Pathology.

Representative Experience

Over his 29 years in the industry, Dr. Dillberger has held positions of increasing responsibility at Marion Merrell Dow, GlaxoWellcome, and Triangle Pharmaceuticals. He served as Head of USA Pathology, Director of Safety Evaluation for USA-Based Development Projects, and Worldwide Specialist in Oncology Drug Projects for GlaxoWellcome and as Director of Toxicology at Triangle Pharmaceuticals. Dr. Dillberger has prepared or helped prepare safety evaluation packages for numerous clinical trial and marketing applications, including the successful NDAs for Coviracil®, Kapvay®, NortheraTM , Triferic®, and Sovaldi® and CTDs for ThelinTM and Tyvaso®.


  • Michigan State University  (Ph.D.)
    • Pathology and Environmental Toxicology
    • Molecular Mechanisms of Carcinogenesis
  • University of Miami
    • School of Medicine and Papanicolaou Cancer Research Institute
    • 3-year residency in Comparative Pathology
  • Iowa State University  (DMV)


Dr. Dillberger was certified in Veterinary Pathology by the American College of Veterinary Pathologists in 1987 and in Toxicology by the American Board of Toxicology in 1992.

In 2001, he became one of a handful of pathologists accepted as a fellow in the International Academy of Toxicologic Pathology, and served as Treasurer for the organization from 2006 to 2012.